KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Capital Employed (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Return on Capital Employed for 12 consecutive years, with 0.42% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 21.0% to 0.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.42% through Dec 2025, up 21.0% year-over-year, with the annual reading at 0.36% for FY2025, 27.0% up from the prior year.
  • Return on Capital Employed hit 0.42% in Q4 2025 for Arbutus Biopharma, up from 0.49% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.33% in Q2 2022 to a low of 0.79% in Q1 2025.
  • Historically, Return on Capital Employed has averaged 0.51% across 5 years, with a median of 0.49% in 2021.
  • Biggest five-year swings in Return on Capital Employed: surged 93bps in 2021 and later decreased -21bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.42% in 2021, then grew by 7bps to 0.39% in 2022, then plummeted by -54bps to 0.61% in 2023, then dropped by -5bps to 0.63% in 2024, then soared by 33bps to 0.42% in 2025.
  • Business Quant data shows Return on Capital Employed for ABUS at 0.42% in Q4 2025, 0.49% in Q3 2025, and 0.57% in Q2 2025.